This high prevalence is a substantial contributor to healthcare costs and a major cause of morbidity. Anti- hypertensive Therapeutics Market forecast 2021.

1
Anti- hypertensive Therapeutics in Asia- Pacific
Markets to 2021- Increasing Prevalence of
Hypertension Drives Market Growth despite Weak
Pipeline
The Global Anti- hypertensive Therapeutics
market is expected to increase in value at a CAGR
of 1.2 from 517 million to 561 million.
Click Here To Check Complete Report
2
Summary of the Report
Hypertension is a chronic medical condition
characterized by elevated blood pressure in the
arteries. It affected an estimated 517 million
people in 2014, a figure that will grow at a
Compound Annual Growth Rate (CAGR) of 1.2 to 561
million in 2021 in the four Asia-Pacific (APAC)
regions of China, India, Australia, and Japan.
This high prevalence is a substantial contributor
to healthcare costs and a major cause of
morbidity. Despite this, awareness of
hypertension is low among physicians, patients,
and the public alike, leading to poor blood
pressure control.The classes of drugs
prescribed to treat hypertension are Angiotensin
Converting Enzyme Inhibitors (ACEI), Angiotensin
Receptor Blockers (ARB), Calcium Channel Blockers
(CCB), beta-blockers, renin inhibitors, and
diuretics. The percentage of patients treated
using monotherapy and combination therapy
(including fixed-dose combinations) varies from
country to country. The most commonly prescribed
drugs in the CCB class are amlodipine and
lercanidipine, while the leading ARBs are
telmisartan, candesartan, olmesartan, irbesartan,
losartan, valsartan, azilsartan medoxomil, and
eprosartan. Ramipril, imidapril, perindopril,
enalapril, lisinopril, benazepril, fosinopril,
trandolapril, and quinapril dominate the ACEIs.
3
Scope of the Report

• Hypertension prevalence is a prominent
  contributor to market size in the assessed
  countries. The market is mostly dominated by
  generics, and there are only a few patented
  products.
• Will generics continue to dominate treatment?
• How do the elderly populations and their
  associated risk factors affect prevalence?
• The current anti-hypertensive therapeutics
  pipeline is weak, comprising 124 molecules in
  various stages of development, dominated by small
  molecules.
• Will the upcoming molecules change the treatment
  paradigm in the near future?
• How will the weak pipeline affect the market?
• How do failure rates vary by product stage of
  development, molecule type, and mechanism of
  action?
• How do other factors such as average trial
  duration and trial size influence the costs and
  risks associated with product development?
• Over the 20142021 forecast periods, the APAC
  anti-hypertensive therapeutics market is expected
  to increase in value at a CAGR of 3.4 from 15.7
  billion to just over 19.9 billion. Growth is
  projected to vary considerably across the four
  assessed markets.

Download Sample Brochure
4
Reasons to Buy

• This report will enable you to  
• Understand the clinical context of hypertension
  by considering symptoms, etiology,
  pathophysiology, co-morbidities and
  complications, epidemiology, diagnosis, and
  treatment options.
• Identify the therapeutic strategies, products,
  and companies that dominate the current marketed
  products landscape, and recognize gaps.
• Appreciate key anti-hypertensive pipeline trends
  in molecule type, administration route, mechanism
  of action, and novelty.
• Consider market opportunities and potential risks
  by examining trends in anti-hypertensive clinical
  trial size, duration, and failure rate by stage
  of development, molecule type, and mechanism of
  action.
• Compare treatment usage patterns, annual therapy
  costs, and market growth projections for the
  China, India, Australia, and Japan.
• Discover trends in licensing and co-development
  deals concerning anti-hypertensive products and
  identify the major strategic consolidations that
  have shaped the commercial landscape.

Make an Inquiry Before Buying
5
Anti- hypertensive Therapeutics in Asia- Pacific
Markets to 2021- Increasing Prevalence of
Hypertension Drives Market Growth despite Weak
Pipeline
A detailed qualitative analysis of the factors
responsible for driving and restraining growth of
the global Anti- hypertensive Therapeutics in
Major Developed Markets and future opportunities
are provided in the report.
Click here to order a copy of Anti- hypertensive
Therapeutics Markets to 2021 Report
Contact 1-302-684-6088 sales_at_marketintelreports.c
om www.marketintelreports.com